Results 131 to 140 of about 955 (158)

Prima-1Met Combined with Bortezomib Has Synergistic Anti-Myeloma Activity By Modulation of Apoptosis and Cell Cycle Regulating Genes

Blood, 2015
Abstract INTRODUCTION Multiple Myeloma (MM) is a plasma-cell malignancy characterized by dismal prognosis and a high level of relapse, thus novel therapeutic approaches are needed. PRIMA-1Met is a novel small molecule showing anti-tumour activity and currently in clinical phase I-II trials.
Priya Khoral, Robert J Guo, Jahangir Abdi, Hong Chang   +3 more
openaire   +1 more source

PRIMA-1MET induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins [PDF]

Oncogene, 2006
We have previously identified PRIMA-1, a low molecular weight compound that restores the transcriptional transactivation function to mutant p53 and induction of apoptosis. To explore the molecular mechanism for PRIMA-1-induced mutant p53-dependent apoptosis, we examined the intracellular distribution of mutant p53 upon treatment with PRIMA-1(MET) by ...
N, Rökaeus, G, Klein, K G, Wiman, L, Szekely, K, Mattsson   +4 more
exaly   +3 more sources

Tumor Suppressor Microrna-29a/b and Microrna-34a Mediate Small Molecule PRIMA-1Met-Induced Aoptosis In Multiple Myeloma Cells By Targeting c-Myc

Blood, 2013
Abstract PRIMA-1Met/APR246 (p53 reactivation and induction of massive apoptosis), is a small molecule with remarkable anti-tumor activities in various human tumor cells, and is currently under phase I/II clinical trial. We have previously demonstrated anti-tumor activity of PRIMA-1Met in multiple myeloma (MM) cells irrespective of p53 ...
Manujendra N. Saha, Yijun Yang, Hong Chang   +2 more
openaire   +1 more source

p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib

European Journal of Cancer, 2016
Intrinsic and acquired resistance of metastatic melanoma to (V600E/K)BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway, represents a major clinical challenge. Given that p53 is capable of antagonising PI3K/AKT activation we hypothesised that pharmacological restoration of p53 activity may increase the ...
Krayem, Mohammad, Journé, Fabrice, Wiedig, Murielle, Morandini, Renato, Najem, Ahmad, Sales, François, van Kempen, Leon, Sibille, Catherine, Awada, Ahmad, Marine, Jean-Christophe, Ghanem, Ghanem Elias   +10 more
openaire   +2 more sources

Antiproliferative activity of quercetin and prima-1met against hct-116 and hct-15 colon cancer cells

International Journal of pharma and Bio Sciences, 2017
CHANDRA SEKHAR PASULA, DR. SAVITHIRI SHIVAKUMAR, YASODHA LAKSHMI T, Y RAJA RATNA REDDY, MANI RAJESH, RAMA MOORHTY S   +5 more
openaire   +1 more source

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

Cells, 2021
Paola Menichini, Paola Monti, Andrea Speciale   +2 more
exaly  

Corrigendum to ‘p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib’[Eur J of Cancer 55 (2016) 98–110]

European Journal of Cancer, 2022
Mohammad Krayem, Fabrice Journe, Murielle Wiedig, Renato Morandini, Ahmad Najem, François Salès, Leon C. van Kempen, Catherine Sibille, Ahmad Awada, Jean-Christophe Marine, Ghanem Ghanem   +10 more
openaire   +1 more source

ESDR324 - Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1MET

2021
openaire   +1 more source

Impaired epithelial differentiation of induced pluripotent stem cells from EEC patients is rescued by APR-246/PRIMA-1MET

Annales de Dermatologie et de Vénéréologie, 2013
I. Petit, E. Aberdam, R. Shalom-Feuerstein, D. Aberdam   +3 more
openaire   +1 more source

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

Cancer Cell, 2009
Pierre Hainaut, Klas G Wiman, Vladimir J N Bykov   +2 more
exaly